NASDAQ:NVTR - Nuvectra Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $3.97 +0.04 (+1.02 %) (As of 05/24/2019 04:00 PM ET)Previous Close$3.97Today's Range$3.9050 - $4.2152-Week Range$3.85 - $25.17Volume612,385 shsAverage Volume257,552 shsMarket Capitalization$70.67 millionP/E RatioN/ADividend YieldN/ABeta-0.19 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Nuvectra Corporation, a neurostimulation medical device company, develops and commercializes neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets. The company offers Algovita, a spinal cord stimulation system for the treatment of chronic intractable pain of the trunk and limbs. It is also developing Virtis, a sacral neuromodulation (SNM) system for the treatment of chronic urinary retention and overactive bladder; and technologies to support other indications, including SNM for the treatment of overactive bladder and deep brain stimulation to treat Parkinson's disease. The company serves hospitals, surgery centers, and medical facilities through a direct sales force and third-party distributors in the United States and Europe. Nuvectra Corporation was founded in 2008 and is headquartered in Plano, Texas. Receive NVTR News and Ratings via Email Sign-up to receive the latest news and ratings for NVTR and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NVTR Previous SymbolNASDAQ:NVTRV CUSIPN/A CIK1648893 Webhttp://www.nuvectramed.com/ Phone214-474-3103Debt Debt-to-Equity Ratio0.56 Current Ratio6.60 Quick Ratio6.07Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$48.83 million Price / Sales1.45 Cash FlowN/A Price / Cash FlowN/A Book Value$4.47 per share Price / Book0.89Profitability EPS (Most Recent Fiscal Year)($3.19) Net Income$-48,130,000.00 Net Margins-98.77% Return on Equity-62.18% Return on Assets-35.90%Miscellaneous Employees197 Outstanding Shares17,800,000Market Cap$70.67 million Next Earnings Date8/6/2019 (Estimated) OptionableOptionable Nuvectra (NASDAQ:NVTR) Frequently Asked Questions What is Nuvectra's stock symbol? Nuvectra trades on the NASDAQ under the ticker symbol "NVTR." How were Nuvectra's earnings last quarter? Nuvectra Corp (NASDAQ:NVTR) issued its quarterly earnings data on Wednesday, May, 1st. The company reported ($0.83) earnings per share for the quarter, missing analysts' consensus estimates of ($0.65) by $0.18. The company had revenue of $11.13 million for the quarter, compared to the consensus estimate of $12.76 million. Nuvectra had a negative net margin of 98.77% and a negative return on equity of 62.18%. View Nuvectra's Earnings History. When is Nuvectra's next earnings date? Nuvectra is scheduled to release their next quarterly earnings announcement on Tuesday, August 6th 2019. View Earnings Estimates for Nuvectra. What price target have analysts set for NVTR? 4 brokerages have issued twelve-month target prices for Nuvectra's shares. Their predictions range from $18.00 to $27.00. On average, they anticipate Nuvectra's share price to reach $21.00 in the next twelve months. This suggests a possible upside of 429.0% from the stock's current price. View Analyst Price Targets for Nuvectra. What is the consensus analysts' recommendation for Nuvectra? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nuvectra in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Nuvectra. Has Nuvectra been receiving favorable news coverage? Press coverage about NVTR stock has trended positive recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Nuvectra earned a daily sentiment score of 2.5 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the near term. Who are some of Nuvectra's key competitors? Some companies that are related to Nuvectra include SeaSpine (SPNE), Pulse Biosciences (PLSE), Iradimed (IRMD), Neuronetics (STIM), Cytosorbents (CTSO), Apyx Medical (APYX), Alphatec (ATEC), Liquidia Technologies (LQDA), Endologix (ELGX), iCAD (ICAD), T2 Biosystems (TTOO), Sensus Healthcare (SRTS), RenovaCare (RCAR), Apollo Endosurgery (APEN) and Motus GI (MOTS). What other stocks do shareholders of Nuvectra own? Based on aggregate information from My MarketBeat watchlists, some companies that other Nuvectra investors own include Allena Pharmaceuticals (ALNA), Fate Therapeutics (FATE), Avinger (AVGR), Biocept (BIOC), Iovance Biotherapeutics (IOVA), Rigel Pharmaceuticals (RIGL), Ampliphi Biosciences (APHB), Aldeyra Therapeutics (ALDX), Apellis Pharmaceuticals (APLS) and Catalyst Biosciences (CBIO). Who are Nuvectra's key executives? Nuvectra's management team includes the folowing people: Dr. Fred B. Parks Ph.D., CEO & Director (Age 72)Mr. Joseph Paul Hanchin, Pres (Age 57)Mr. Walter Z. Berger, COO, CFO & Exec. VP (Age 63)Ms. Jennifer J. Kosharek, VP, Controller & Principal Accounting Officer (Age 38)Mr. Benjamin Tranchina, Chief Technology Officer Who are Nuvectra's major shareholders? Nuvectra's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.67%), Gilder Gagnon Howe & Co. LLC (5.75%), Dimensional Fund Advisors LP (4.29%), Cannell Capital LLC (4.06%), Peregrine Capital Management LLC (3.66%) and Wells Fargo & Company MN (3.12%). Company insiders that own Nuvectra stock include Benjamin Tranchina, David D Johnson, Joseph Paul Hanchin, Scott F Drees and Thomas Edward Zelibor. View Institutional Ownership Trends for Nuvectra. Which institutional investors are selling Nuvectra stock? NVTR stock was sold by a variety of institutional investors in the last quarter, including Schonfeld Strategic Advisors LLC, BlackRock Inc., Gilder Gagnon Howe & Co. LLC, Peregrine Capital Management LLC, Connor Clark & Lunn Investment Management Ltd., Northern Trust Corp, Parametric Portfolio Associates LLC and Essex Investment Management Co. LLC. View Insider Buying and Selling for Nuvectra. Which institutional investors are buying Nuvectra stock? NVTR stock was bought by a variety of institutional investors in the last quarter, including Cannell Capital LLC, Neuberger Berman Group LLC, Wells Fargo & Company MN, Meitav Dash Investments Ltd., Assenagon Asset Management S.A., Marshall Wace LLP, Gabelli Funds LLC and Penn Capital Management Co. Inc.. Company insiders that have bought Nuvectra stock in the last two years include Benjamin Tranchina, David D Johnson, Scott F Drees and Thomas Edward Zelibor. View Insider Buying and Selling for Nuvectra. How do I buy shares of Nuvectra? Shares of NVTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Nuvectra's stock price today? One share of NVTR stock can currently be purchased for approximately $3.97. How big of a company is Nuvectra? Nuvectra has a market capitalization of $70.67 million and generates $48.83 million in revenue each year. The company earns $-48,130,000.00 in net income (profit) each year or ($3.19) on an earnings per share basis. Nuvectra employs 197 workers across the globe. What is Nuvectra's official website? The official website for Nuvectra is http://www.nuvectramed.com/. How can I contact Nuvectra? Nuvectra's mailing address is 5830 GRANITE PKWY SUITE 1100, PLANO TX, 75024. The company can be reached via phone at 214-474-3103 or via email at [email protected] MarketBeat Community Rating for Nuvectra (NASDAQ NVTR)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 182 (Vote Outperform)Underperform Votes: 175 (Vote Underperform)Total Votes: 357MarketBeat's community ratings are surveys of what our community members think about Nuvectra and other stocks. Vote "Outperform" if you believe NVTR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVTR will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/25/2019 by MarketBeat.com StaffFeatured Article: Stock Symbols, CUSIP and Other Stock Identifiers Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.